Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAs one of the current most popular therapies, agonistic antibodies have been shown to be effective at regulating tumor regression in a wide variety of cancer types. Creative Biolabs provides a series of anti-STING agonistic antibody discovery and development services for our clients all over the world. Equipped with a team of professional scientists, we are capable of providing you with a wide spectrum of customized services on STING. We can accommodate the specific properties of your project and provide flexible integrated solutions.
The stimulator of interferon gene, also known as STING, ERIS, and TMEM173, is a member of the transmembrane protein family and is responsible for regulating immune responses in mammals. Previous studies suggest that STING can produce type I interferon (IFN) when the occurrence of infections to activate the innate immunity against various pathogens, including different kinds of viruses, bacteria, and parasites. Scientists have theorized that it can be expressed in a number of cell types, such as T cells, dendritic cells (DCs), as well as macrophages. Meanwhile, recent researchers have demonstrated that STING pathway or type I IFN profile is associated with T cell responses against different types of tumor cells in pre-clinical trials or clinical trials. As a result, a wide variety of anti-STING agonistic antibodies, like c-di-GMP and c-di-AMP, have been developed to enhance the strong immune response in patients or animal models. Additionally, actions have already been taken to boost the anti-tumor response of anti-STING agonistic antibodies by using several agents or adding some antibodies. The data illustrated that these methods can efficiently improve the efficacy of the induced immune response in tumor models.
Fig.1 Type I IFNs and the STING pathway in cancer. (Corrales, 2015)
STING has been considered as a key factor for therapeutic antibody development in a wide collection of disease therapy. In recent years, a variety of anti-STING agonistic antibodies have also been generated and used for a range of cancer immunotherapies. As an expert in agonistic antibody development, Creative Biolabs has established a panel of assays to develop various types of anti-STING antibodies for disease treatment, especially for cancers. Recent work conducted by our labs has revealed that stimulation of anti-tumor activity by anti-STING agonistic antibodies can trigger enough immune response to induce tumor regression in mice models. Additionally, we also have developed a novel platform for enhancing the efficacy of anti-STING agonistic antibodies and innate immunity against tumor cells. In this platform, agents and antibodies can be widely used for inducing efficient antigen presentation and T cell activity in both in vivo and in vitro studies. For instance, the combination of antibodies, such as PD-1, CTLA-4, and anti-STING agonistic antibodies have been designed for activating a variety of immune responses to break immune suppression of the tumor microenvironment. The results have illustrated that blockade of PD-1 can control tumor growth, leading to a cure of more than 50% in rat models. As a consequence, our anti-STING agonistic antibody services will provide a unique rationale for cancer immunotherapy in the future.
Fig.2 Custom Anti-STING Agonistic Antibody Development Service.
With the commitment of being your best antibody development partner, Creative Biolabs has established the utmost efficient integrated solutions to innovate and accelerate your agonistic antibody development for various types of diseases, especially for malignant tumors. We have won a good reputation among our worldwide customers for successfully accomplishing numerous challenging projects on anti-STING agonistic antibodies. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us to get more information and a quote for your project details.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
